background preloader

Sushilsuri

Facebook Twitter

Success of Morepen Sushil Suri. Dr. Morepen Sushil Suri Background. About Morepen Laboratories Ltd. Director Mr. Sushil Suri. Morepen Laboratories Scores No 1 Position Globally For Its Bulk Drug Montelukast News. Dr. Morepen Sushil suri. This was disclosed by Mr.

Dr. Morepen Sushil suri

Sushil Suri, Chairman and Managing Director, Morepen Laboratories Ltd. after the company’s board meeting, which discussed and took on record the fourth quarter and annual results of the company for the financial year 2015-16. “After attaining leadership in Loratadine, by being world’s largest generic supplier of the bulk drug, Morepen Laboratories Ltd. has attained a leadership in its second molecule -Montelukast,” he pointed out.

Morepen Laboratories Ltd. has reported an over 25-fold increase in its net profit for the financial year ended March 31, 2016. The net profit increased from Rs. 58 lakhs in FY 2014 -15 to Rs. 15.78 crore in FY 2015-16. The total operating revenue in FY 2015-16 stood at Rs. 452.46 crore as against Rs. 370.26 crore in the previous fiscal, registering a growth of 22.20 per cent. Best Chairman and Managing Director Mr. Sushil Suri. About Dr. Morepen Sushil suri. Morepen Sushil Suri - Chairman and Managing Director of Morepen.